The CHMP recommended conditional marketing authorization ... All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may ...

Earlier this week, the European Commission followed the advice of its human medicines advisory committee, the CHMP, and revoked ... remains valid until further notice. In a statement, Advanz ...

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company"), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Vyjuvek ...

The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene.

The commission last month asked the CHMP to consider whether the new information would require an update of the positive opinion, and to consider whether the wording of the risk minimization ...

The North Chicago, Ill., biopharmaceutical company said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the first half of the year.